肿瘤学：A novel anti-PD-1/VEGF bispecific fusion protein with enhanced VEGF binding capacity and developability for synergistic immunotherapy.

原文摘录：Combination therapy targeting PD-1 and VEGF has demonstrated significant clinical benefits in multiple cancers. However, developing a single-molecule bispecific agent capable of simultaneously blocking both pathways with enhanced VEGF-binding capacity rem … These findings highlight PKVBP as a promising bispecific candidate with superior VEGF-blocking capability and favorable developability, supporting its further investigation for synergistic cancer immunotherapy